tag:blogger.com,1999:blog-6117490577046720540.post-3814868605105802542007-08-04T04:42:00.000-07:002007-08-04T06:24:52.059-07:00<h2 align="center">Description</h2><br /><p>Phentermine hydrochloride USP has the chemical name of<br />alpha, alpha-Dimethylphenethylamine hydrochloride. The structural formula is as<br />follows:<br /><img id="BLOGGER_PHOTO_ID_5094830694598877682" src="http://2.bp.blogspot.com/_CeIoLH3KxzY/RrR5he5SofI/AAAAAAAAAAU/gLgOAoZuKik/s320/image001.jpg" border="0" /><br /><br />phentermine (Phentermine) chemical structure<br /><br /><div class="ac"></div><br />Phentermine hydrochloride is a white, odorless,<br />hygroscopic, crystalline powder which is soluble in water and lower alcohols,<br />slightly soluble in chloroform and insoluble in ether.<br />Phentermine®, an anorectic agent for oral administration, is<br />available as a capsule or tablet containing 37.5 mg of phentermine<br />hydrochloride (equivalent to 30 mg of phentermine base).<br />Phentermine® Capsules contain the inactive ingredients Corn<br />Starch, Gelatin, Lactose Monohydrate, Magnesium Stearate, Titanium Dioxide,<br />Black Iron Oxide, FD&amp;C Blue #1, FD&C Red #40 and D&amp;C Red #33.<br />Phentermine® Tablets contain the inactive ingredients Corn<br />Starch, Lactose (Anhydrous), Magnesium Stearate, Microcrystalline Cellulose,<br />Pregelatinized Starch, Sucrose, and FD&C Blue #1. Phentermine weight loss<div class="ac"></div><br /><br /><br /><h2 align="center">Contraindications</h2><br /><p>Advanced arteriosclerosis, cardiovascular disease, moderate<br />to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy<br />to the sympathomimetic amines, glaucoma.<br />Agitated states.<br />Patients with a history of drug abuse.<br />During or within 14 days following the administration of<br />monoamine oxidase inhibitors (hypertensive crises may result). Phentermine weight loss.<div class="ac"></div><br /></p><h2 align="center">Clinical Pharmacology</h2><br /><p>Phentermine® is a sympathomimetic amine with pharmacologic<br />activity similar to the prototype drugs of this class used in obesity, the<br />amphetamines. Actions include central nervous system stimulation and elevation<br />of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all<br />drugs of this class in which these phenomena have been looked for.<br />Drugs of this class used in obesity are commonly known as<br />"anorectics" or "anorexigenics". It has not been<br />established that the action of such drugs in treating obesity is primarily one<br />of appetite suppression. Other central nervous system actions, or metabolic<br />effects, may be involved, for example.<br />Adult obese subjects instructed in dietary management and<br />treated with "anorectic" drugs lose more weight on the average than<br />those treated with placebo and diet, as determined in relatively short-term<br />clinical trials.<div class="ac"></div><br />The magnitude of increased weight loss of drug-treated patients<br />over placebo-treated patients is only a fraction of a pound a week. The rate of<br />weight loss is greatest in the first weeks of therapy for both drug and placebo<br />subjects and tends to decrease in succeeding weeks. The possible origins of the<br />increased weight loss due to the various drug effects are not established. The<br />amount of weight loss associated with the use of an "anorectic" drug<br />varies from trial to trial, and the increased weight loss appears to be related<br />in part to variables other than the drugs prescribed, such as the<br />physician-investigator, the population treated and the diet prescribed. Studies<br />do not permit conclusions as to the relative importance of the drug and<br />non-drug factors on weight loss.<br />The natural history of obesity is measured in years,<br />whereas the studies cited are restricted to a few weeks duration; thus, the<br />total impact of drug-induced weight loss over that of diet alone must be<br />considered clinically limited. Phentermine weight loss.<br /></p><div class="ac"></div><h2 align="center">Warnings</h2><br /><p>Phentermine® is indicated only as short-term<br />monotherapy for the management of exogenous obesity. The safety and efficacy of<br />combination therapy with phentermine and any other drug products for weight<br />loss, including selective serotonin reuptake inhibitors (e.g., fluoxetine,<br />sertraline, fluvoxamine, paroxetine), have not been established. Therefore,<br />coadministration of these drug products for weight loss is not recommended.<br />Primary Pulmonary Hypertension (PPH) - a rare,<br />frequently fatal disease of the lungs - has been reported to occur in patients<br />receiving a combination of phentermine with fenfluramine or dexfenfluramine.<br />The possibility of an association between PPH and the use of phentermine alone<br />cannot be ruled out; there have been rare cases of PPH in patients who<br />reportedly have taken phentermine alone. The<br />initial symptom of PPH is usually dyspnea. Other initial symptoms include:<br />angina pectoris, syncope or lower extremity edema. Patients should be advised<br />to report immediately any deterioration in exercise tolerance. Treatment should<br />be discontinued in patients who develop new, unexplained symptoms of dyspnea,<br />angina pectoris, syncope or lower extremity edema.<br />Valvular Heart Disease: Serious regurgitant cardiac<br />valvular disease, primarily affecting the mitral, aortic and/or tricuspid<br />valves, has been reported in otherwise healthy persons who had taken a<br />combination of phentermine with fenfluramine or dexfenfluramine for weight<br />loss. The etiology of these valvulopathies has not been established and their<br />course in individuals after the drugs are stopped is not known. The possibility<br />of an association between valvular heart disease and the use of phentermine<br />alone cannot be ruled out; there have been rare cases of valvular heart disease<br />in patients who reportedly have taken phentermine alone.<div class="ac"></div><br />Tolerance to the anorectic effect usually develops within a<br />few weeks. When this occurs, the recommended dose should not be exceeded in an<br />attempt to increase the effect; rather, the drug should be discontinued.<br />Phentermine® may impair the ability of the patient to engage<br />in potentially hazardous activities such as operating machinery or driving a<br />motor vehicle; the patient should therefore be cautioned accordingly. Phentermine weight loss.<br /></p><div class="ac"></div><h2 align="center">Indications and Usage</h2><br /><p>Phentermine® (phentermine hydrochloride) is indicated as a<br />shortterm (a few weeks) adjunct in a regimen of weight reduction based on<br />exercise, behavioral modification and caloric restriction in the management of<br />exogenous obesity for patients with an initial body mass index &gt;=30 kg/m2,<br />or &gt;=27 kg/m2 in the presence of other risk factors (e.g., hypertension,<br />diabetes, hyperlipidemia).<div class="ac"></div><br />Below is a chart of Body Mass Index (BMI) based on various<br />heights and weights.<br />BMI is calculated by taking the patient's weight, in<br />kilograms (kg), divided by the patient's height, in meters (m), squared. Metric<br />conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. </p><p><br />BODY MASS INDEX (BMI), kg/m2<br /><a href="http://3.bp.blogspot.com/_CeIoLH3KxzY/RrR8yu5SohI/AAAAAAAAAAk/-jNNwmG7Tfk/s1600-h/image002.jpg"><img id="BLOGGER_PHOTO_ID_5094834289486504466" style="CURSOR: hand" alt="" src="http://3.bp.blogspot.com/_CeIoLH3KxzY/RrR8yu5SohI/AAAAAAAAAAk/-jNNwmG7Tfk/s320/image002.jpg" border="0" /></a><br />Height (feet, inches)<br /><br />phentermine (Phentermine) chart of body mass index (BMI)<br />The limited usefulness of agents of this class (see<br />Clinical Pharmacology) should be measured against possible risk factors<br />inherent in their use such as those described below. Phentermine weight loss.</p><div class="ac"></div><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6117490577046720540-381486860510580254?l=phentermine-weight-loss.blogspot.com'/></div>Phentermine weight losshttp://www.blogger.com/profile/01272570328698045414noreply@blogger.com